Xiangya Hospital of

Company snapshot

Founded in 1906 and located in Changsha, Xiangya Hospital Central South University is a Class-A Grade-3 (top level in China) general hospital under the direct supervision of the National Health Commission, an affiliated hospital of Central South University directly under the Ministry of Education, and an important center for clinical care, medical education and scientific and technological innovat

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Xiangya Hospital of. Not investment advice.

• What is Xiangya Hospital of?

  Second Xiangya Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Acute Coronary Syndrome. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, an

• Is Xiangya Hospital of publicly traded?

  Xiangya Hospital of appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Xiangya Hospital of develop or market?

  We link 1 drug profile(s) where Xiangya Hospital of is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/second-xiangya-hospital-of-central-south-university#company-drugs.

• What are the latest developments for Xiangya Hospital of?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Xiangya Hospital of focus on?

  Xiangya Hospital of focuses on Acute Coronary Syndrome based on our analysis of their pipeline programs and drug development activities.